Herpes Zoster (Shingles) Vaccination After Autologous HSCT

​A phase 3 clinical trial reports that two doses of the adjuvanted recombinant zoster vaccine reduce the incidence of herpes zoster, commonly known as shingles, following autologous hematopoietic stem cell transplantation (HSCT). Patients receiving high-dose chemotherapy for certain types of malignancies, including multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, acute myeloid leukemia, neuroblastoma, and germ cell tumors, are often administered autologous HSCT in order to replenish the...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.